Norris Perne & French’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.7M Buy
61,970
+631
+1% +$147K 0.92% 25
2026
Q1
$15M Sell
61,339
-125,261
-67% -$29.2M 1% 23
2025
Q4
$38.6M Sell
186,600
-5,272
-3% -$1.04M 2.55% 10
2025
Q3
$35.6M Buy
191,872
+236
+0.1% +$40.4K 2.46% 11
2025
Q2
$29.3M Buy
191,636
+4,232
+2% +$651K 2.04% 16
2025
Q1
$31.1M Buy
187,404
+61
+0% +$9.54K 2.34% 9
2024
Q4
$27.1M Buy
187,343
+121
+0.1% +$18.8K 1.95% 15
2024
Q3
$30.3M Buy
187,222
+33,018
+21% +$5.26M 2.08% 13
2024
Q2
$22.5M Buy
154,204
+46,876
+44% +$6.97M 1.63% 19
2024
Q1
$17M Buy
107,328
+4,203
+4% +$669K 1.22% 37
2023
Q4
$16.2M Buy
103,125
+4,157
+4% +$637K 1.25% 36
2023
Q3
$15.4M Buy
98,968
+1,916
+2% +$316K 1.35% 33
2023
Q2
$16.1M Buy
97,052
+4,392
+5% +$709K 1.35% 32
2023
Q1
$14.4M Buy
92,660
+4,901
+6% +$791K 1.32% 37
2022
Q4
$15.5M Buy
87,759
+2,015
+2% +$348K 1.53% 26
2022
Q3
$14M Buy
85,744
+1,467
+2% +$248K 1.46% 29
2022
Q2
$15M Sell
84,277
-52,381
-38% -$9.33M 1.44% 29
2022
Q1
$24.2M Sell
136,658
-811
-0.6% -$138K 1.96% 9
2021
Q4
$23.5M Sell
137,469
-13,306
-9% -$2.18M 1.82% 14
2021
Q3
$24.4M Sell
150,775
-263
-0.2% -$44.9K 2.09% 10
2021
Q2
$24.9M Buy
151,038
+1,883
+1% +$312K 2.14% 9
2021
Q1
$24.5M Sell
149,155
-12,593
-8% -$2.04M 2.27% 8
2020
Q4
$25.5M Buy
161,748
+21,265
+15% +$3.14M 2.4% 6
2020
Q3
$20.9M Buy
140,483
+2,928
+2% +$433K 2.27% 11
2020
Q2
$19.3M Sell
137,555
-5,591
-4% -$815K 2.35% 10
2020
Q1
$18.8M Buy
143,146
+20,096
+16% +$2.85M 2.82% 6
2019
Q4
$17.9M Buy
123,050
+9,074
+8% +$1.23M 2.14% 10
2019
Q3
$14.7M Buy
113,976
+2,700
+2% +$356K 1.84% 17
2019
Q2
$15.5M Buy
111,276
+1,329
+1% +$184K 1.96% 15
2019
Q1
$15.4M Buy
109,947
+6,301
+6% +$844K 2.02% 13
2018
Q4
$13.4M Buy
103,646
+1,157
+1% +$161K 2.09% 11
2018
Q3
$14.2M Buy
102,489
+1,311
+1% +$174K 1.85% 13
2018
Q2
$12.3M Buy
101,178
+22,201
+28% +$2.77M 1.79% 15
2018
Q1
$10.1M Buy
78,977
+10,837
+16% +$1.46M 1.47% 27
2017
Q4
$9.52M Buy
68,140
+591
+0.9% +$82.3K 1.38% 29
2017
Q3
$8.78M Buy
67,549
+1,502
+2% +$199K 1.37% 28
2017
Q2
$8.74M Sell
66,047
-355
-0.5% -$45.3K 1.47% 23
2017
Q1
$8.27M Sell
66,402
-14,639
-18% -$1.75M 1.54% 18
2016
Q4
$9.34M Sell
81,041
-1,418
-2% -$164K 1.84% 14
2016
Q3
$9.74M Sell
82,459
-1,192
-1% -$145K 2.03% 14
2016
Q2
$10.1M Sell
83,651
-4,127
-5% -$469K 2.19% 14
2016
Q1
$9.5M Buy
87,778
+11,877
+16% +$1.23M 1.97% 21
2015
Q4
$7.8M Sell
75,901
-2,674
-3% -$269K 1.63% 22
2015
Q3
$7.33M Sell
78,575
-200
-0.3% -$19.3K 1.76% 25
2015
Q2
$7.68M Sell
78,775
-5,265
-6% -$527K 1.47% 29
2015
Q1
$8.45M Sell
84,040
-6,595
-7% -$671K 1.57% 27
2014
Q4
$9.48M Sell
90,635
-48
-0.1% -$5.06K 1.73% 24
2014
Q3
$9.67M Sell
90,683
-5,100
-5% -$529K 1.87% 19
2014
Q2
$10M Sell
95,783
-631
-0.7% -$63.8K 1.89% 20
2014
Q1
$9.47M Sell
96,414
-1,988
-2% -$184K 1.86% 20
2013
Q4
$9.01M Sell
98,402
-1,424
-1% -$131K 1.69% 22
2013
Q3
$8.65M Buy
99,826
+675
+0.7% +$60.6K 1.78% 19
2013
Q2
$8.51M Buy
+99,151
New +$8.41M 1.82% 15

Other funds holding JNJ

Norris Perne & French's JNJ Position: Q2 2026 in Review

Norris Perne & French increased its Johnson & Johnson (JNJ) stake by 1% in Q2 2026, buying an estimated $147K and bringing the position to 61,970 shares worth $15.7M. The position accounts for 0.92% of the portfolio, ranked #25.

Norris Perne & French first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. The position peaked at $38.6M in Q4 2025. 2,379 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Norris Perne & French held 61,970 shares of Johnson & Johnson worth $15.7M as of Q2 2026.
  • Norris Perne & French bought 631 Johnson & Johnson shares in Q2 2026, an estimated $147K.
  • Johnson & Johnson made up 0.92% of Norris Perne & French's portfolio in Q2 2026, its #25 holding.
  • Norris Perne & French first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • Norris Perne & French's Johnson & Johnson position peaked at $38.6M in Q4 2025.
  • 2,379 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Norris Perne & French's 13F filing for Q2 2026, filed 21 Jul 2026.